Journal of Vascular Surgery
Volume 47, Issue 4 , Pages 744-751 , April 2008

A prospective evaluation of C-reactive protein in the progression of carotid artery stenosis

Presented at the Twenty-second Annual Meeting of the Western Vascular Society, Kona, Hawaii, Sept 8-11, 2007.

  • Zachary M. Arthurs, MD

      Affiliations

    • Madigan Army Medical Center, Tacoma, Wash
    • Corresponding Author InformationReprint requests: Zachary M. Arthurs, MD, Madigan Army Medical Center, Department of Surgery, 3032 Ridge View Place, DuPont, WA 98327.
    • ,
  • Charles Andersen, MD

      Affiliations

    • Madigan Army Medical Center, Tacoma, Wash
    • ,
  • Benjamin W. Starnes, MD

      Affiliations

    • University of Washington, Seattle, Wash
    • ,
  • Vance Y. Sohn, MD

      Affiliations

    • Madigan Army Medical Center, Tacoma, Wash
    • ,
  • Philip S. Mullenix, MD

      Affiliations

    • Walter Reed Army Medical Center, Washington, DC.
    • ,
  • Jason Perry, MD

      Affiliations

    • Madigan Army Medical Center, Tacoma, Wash

Received 5 September 2007 ,Accepted 29 November 2007.

References 

  1. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis. 1999;10(Suppl 1):S9–S12
  2. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–242
  3. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–771
  4. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(4 Suppl S):37S–42S
  5. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  6. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25:401–408
  7. Lombardo A, Biasucci LM, Lanza GA, Coli S, Silvestri P, Cianflone D, et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation. 2004;109:3158–3163
  8. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108:166–170
  9. Tanne D, Benderly M, Goldbourt U, Haim M, Tenenbaum A, Fisman EZ, et al. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke. 2006;37:1720–1724
  10. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg. 2003;38:1018–1024
  11. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004;148(1 Suppl):S19–S26
  12. Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA. C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis. Arch Surg. 2007;(Accepted, in press)
  13. Mullenix P, Steele S, Martin M, Starnes B, Andersen C. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of carotid stenosis. J Am Coll Surg. 2004;194(3S):S105
  14. Moneta GL, Edwards JM, Papanicolaou G, Hatsukami T, Taylor LM, Strandness DE, et al. Screening for asymptomatic internal carotid artery stenosis: duplex criteria for discriminating 60% to 99% stenosis. J Vasc Surg. 1995;21:989–994
  15. Carpenter JP, Lexa FJ, Davis JT. Determination of sixty percent or greater carotid artery stenosis by duplex Doppler ultrasonography. J Vasc Surg. 1995;22:697–703discussion 703-5
  16. Mansour MA, Littooy FN, Watson WC, Blumofe KA, Heilizer TJ, Steffen GF, et al. Outcome of moderate carotid artery stenosis in patients who are asymptomatic. J Vasc Surg. 1999;29:217–225discussion 225-7
  17. Muluk SC, Muluk VS, Sugimoto H, Rhee RY, Trachtenberg J, Steed DL, et al. Progression of asymptomatic carotid stenosis: a natural history study in 1004 patients. J Vasc Surg. 1999;29:208–214discussion 214-6
  18. Blackburn R, Giral P, Bruckert E, Andre JM, Gonbert S, Bernard M, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2001;21:1962–1968
  19. Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke. 2006;37:351–357
  20. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R, et al. Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS). Circulation. 2005;111:2203–2209
  21. Phan BA, Chu B, Polissar N, Hatsukami TS, Yuan C, Zhao XQ. Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging. Int J Cardiovasc Imaging. 2007;23:337–342
  22. Zhao XQ, Yuan C, Hatsukami TS, Frechette EH, Kang XJ, Maravilla KR, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol. 2001;21:1623–1629
  23. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70
  24. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol. 2002;40:49–55
  25. Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med. 2003;114:485–494

 Competition of interest: none.Disclaimer: The opinions expressed in this article do not necessarily reflect those of the United States Government, the US Department of Defense, or Madigan Army Medical Center.CME article

PII: S0741-5214(07)01960-X

doi: 10.1016/j.jvs.2007.11.066

Journal of Vascular Surgery
Volume 47, Issue 4 , Pages 744-751 , April 2008

Article Tools

* Image Usage & Resolution